Skip to main content

Market Overview

Mid-Morning Market Update: Markets Mostly Lower; Twitter Shares Fall Following Q2 Results


Following the market opening Friday, the Dow traded up 0.02 percent to 25,531.97 while the NASDAQ declined 0.34 percent to 7,825.23. The S&P also fell, dropping 0.13 percent to 2,833.61.

Leading and Lagging Sectors

Friday morning, the telecommunication services shares climbed 1.7 percent. Meanwhile, top gainers in the sector included Telecom Italia S.p.A. (NYSE: TI) up 5 percent, and BT Group plc (NYSE: BT) up 5 percent.

In trading on Friday, energy shares fell 0.62 percent.

Top Headline

Twitter Inc (NYSE: TWTR) shares fell around 17 percent in reaction to second-quarter results.

MAUs totaled 335 million, with 267 million accounted for by international customers and 68 million by U.S. customers. The year-over-year increase was 9 million, but the figure was down 1 million from Q1. Average daily active users climbed 11 percent, faster than the 10-percent growth in Q1, extending the streak of double-digit year-over-year growth to seven quarters.

The social networking platform reported non-GAAP earnings per share of 17 cents in Q2 compared to 8 cents per share one year ago. Twitter's quarterly revenue rose 24 percent year-over-year to $711 million. Analysts, on average, estimated EPS of 17 cents per share on revenues of $696.23 million.

Equities Trading UP

Atlassian Corporation Plc (NASDAQ: TEAM) shares shot up 14 percent to $76.37 following Q4 sales beat and announcement that the company has made an investment in Slack.

Shares of BJ's Restaurants, Inc. (NASDAQ: BJRI) got a boost, shooting up 10 percent to $67.40 after reporting a second-quarter earnings beat.

SPS Commerce, Inc. (NASDAQ: SPSC) shares were also up, gaining 13 percent to $86.78 after the company posted upbeat Q2 results.

Equities Trading DOWN

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares dropped 64 percent to $1.41 in reaction to a disappointing update relating to a clinical trial. The company said it will stop a Phase 3 study of its Tonmya therapy in military-related posttraumatic stress disorder due to inadequate separation from placebo on the primary endpoint at week 12.

Shares of American Midstream Partners, LP (NYSE: AMID) were down 41 percent to $6.85 after the company reported a revised capital allocation strategy and Q2 common unit distribution.

Cellectar Biosciences, Inc. (NASDAQ: CLRB) was down, falling around 37 percent to $3.40. Cellectar Biosciences priced its public offering for gross proceeds of $14.4 million.


In commodity news, oil traded down 0.19 percent to $69.48 while gold traded down 0.18 percent to $1,233.10.

Silver traded up 0.03 percent Friday to $15.50, while copper fell 0.11 to $2.815.


European shares were higher today. The eurozone’s STOXX 600 climbed 0.39 percent, the Spanish Ibex Index rose 0.64 percent, while Italy’s FTSE MIB Index rose 0.06 percent. Meanwhile the German DAX climbed 0.53 percent, and the French CAC 40 rose 0.34 percent while U.K. shares rose 0.60 percent.


The U.S. economy expanded at an annual rate of 4.1 percent for the second quarter, compared to a revised 2.2 percent rate in the prior quarter.

The University of Michigan's consumer sentiment index rose to 97.90 for July, versus prior reading of 97.10. Economists were expecting a reading of 97.10.

The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.


Related Articles (BJRI + AMID)

View Comments and Join the Discussion!

Posted-In: Mid-Morning Market UpdateNews Eurozone Commodities Global Intraday Update Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at